The nation of Zimbabwe has rejected a major US health deal valued at $367m (£272m) spanning five years because of the United States' demand for sensitive biological samples.
This rejection became public after a government memo dated December was leaked, which showed Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government spokesman has since clarified that the United States was requesting health data for scientific study and profit but refused to guarantee the benefits from any future treatments.
"We will now turn to the difficult and regrettable process of scaling back our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had provided over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for further dialogue to find a agreement agreeable to all parties so the country's critical HIV treatment initiative can continue.
Broader Background
This development comes after a similar case in Kenya, where a court halted a related deal with the US after concerns were raised about the safety of Kenyans' health data.
Since returning to office recently, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
USAID had managed assistance for the American government, but Trump claimed its spending was "wasteful" and his administration was pursuing direct bilateral deals to boost openness and responsibility.
Based on statements, 16 nations in Africa have so far agreed to these new health pacts, representing over $18.3bn in new funding.
Details of the Rejected Deal
This assistance for Zimbabwe would have gone towards "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this collaboration would have delivered significant benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently receiving HIV treatment via US-supported programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the proposed deal was "unequal".
"Our nation was requested to provide its biological resources and data indefinitely, without any equivalent promise of benefiting from any medical innovations – like new medicines or tests – that might result from that provided information," Mangwana explained.
"Put simply, our country would supply the basic resources for medical research with no assurance that the final treatments would be accessible to our people if a new pandemic emerge."
National Interest and International Frameworks
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were disrupting structures already set up through the global health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing system created to manage potential pandemics.
"This mechanism is intended to guarantee that when a country contributes its samples, the resulting advantages – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the funds to develop them."
Zimbabwe's reservations over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We are open to ongoing discussions with our American counterparts on how future co-operation might be designed in a way that honours the independence and dignity of both nations."
Medical Community Response
Medical experts stated it understood the government's concerns, but recommended that talks should continue considering a large portion of the nation's Aids initiatives depended on external financing.
"In cases where specific concerns exist, such as those relating to information security or implementation frameworks, these can often be addressed through technical clarification and negotiated safeguards," the group commented.
The halted deal highlights the ongoing challenges between accepting vital international aid and safeguarding national sovereignty in an increasingly data-driven world.